Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Rhea-AI Summary

Arbutus Biopharma (Nasdaq: ABUS) has announced its participation in the H.C Wainwright @ Home virtual fireside chat series, scheduled for December 3, 2024, at 11:00 am ET. The event will be accessible via webcast on the company's investor relations website.

Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection. Their approach combines HBV DNA suppression, surface antigen reduction, and immune response boosting. The company's pipeline includes imdusiran (AB-729), an RNAi therapeutic showing promising functional cure rates in combination therapy, and AB-101, an oral PD-L1 inhibitor currently in Phase 1a/1b clinical trials.

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus’ pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When is Arbutus Biopharma (ABUS) participating in the H.C Wainwright fireside chat?

Arbutus Biopharma is participating in the H.C Wainwright @ Home virtual fireside chat on Tuesday, December 3, 2024, at 11:00 am ET.

What are the main drug candidates in Arbutus Biopharma's (ABUS) pipeline?

Arbutus Biopharma's pipeline includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor currently in Phase 1a/1b clinical trials.

What is the therapeutic focus of Arbutus Biopharma (ABUS)?

Arbutus Biopharma focuses on developing a functional cure for chronic hepatitis B virus (cHBV) infection through a combination of HBV DNA suppression, surface antigen reduction, and immune response boosting.

How can investors access the Arbutus Biopharma (ABUS) H.C Wainwright fireside chat?

Investors can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations.